News Articles and Montana BioScience Alliance Newsletters
A total of 457 patients were enrolled in this multi-site study in the U.S. Topline results are expected in late December 2023. If successful, it is expected to be the final, well-controlled efficacy trial required for submission of a New Drug Application (NDA) for approval by the U.S. Food and Drug Administration (FDA).
FYR Diagnostics, a pioneering company in the development of liquid biopsy technologies, is thrilled to announce the addition of Dr. Kirk Tanner and Dr. Andy Hill to its Scientific Advisory Board.
A vaccine for tuberculosis exists, but TB is still the 2nd leading infectious killer in the world after Covid-19, according to the World Health Organization. With a $12.3 million contract from the National Institutes of Health, researchers at the University of Montana are hoping to improve the vaccine for TB and positively influence global health.
Children with Autism Spectrum Disorder are at Risk for Low Bone Density. Preliminary Data Suggest that the Administration of Oxytocin May Favorably Impact Bone Formation and Strength
It’s entirely possible that the secret to understanding — perhaps even vanquishing — the coronavirus rests in this quiet town of 5,000 nestled at the edge of the wilderness.
When her husband was undergoing cancer treatment, Cindy Perez of Southwest Ranches, Fla., learned about a new blood test that could help find early cancers. The 50-year-old said she felt fine, but her husband urged her to take the test anyway.
Studies of interactions between two lab-generated monoclonal antibodies (mAbs) and an essential Epstein-Barr virus (EBV) protein have uncovered targets that could be exploited in designing treatments and vaccines for this extremely common virus.
As a new year begins in Congress, the Biotechnology Innovation Organization (BIO) is carrying over many of its legislative priorities from last year.
Administrative Supplements to Promote Diversity in Research and Development Small Businesses – SBIR/STTR
Contract Pre-solicitation for R&D that will contribute toward ARPA-H mission needs and SBIR program objectives.
View the Spring 2024 Newsletter now!
View the Winter II 2024 Newsletter now!